Navigation Links
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
Date:6/2/2009

ission among the overall randomized population (N=508), including individuals who did not enter the study extension and were assumed to be non-responders to therapy or not in steroid-free remission at week 50, was 46 percent of patients receiving REMICADE and azathioprine combination therapy, and 35 percent of patients receiving REMICADE monotherapy, compared with 24 percent of patients receiving azathioprine alone (P < 0.001 REMICADE with azathioprine vs. azathioprine monotherapy; P = 0.028 REMICADE monotherapy vs. azathioprine monotherapy; P = 0.035 REMICADE with azathioprine vs. REMICADE monotherapy). In an analysis of only those individuals participating in the extension (N=280), 72 percent of patients receiving REMICADE and azathioprine combination therapy, 61 percent of patients receiving REMICADE monotherapy and 55 percent receiving azathioprine alone achieved steroid-free remission at week 50 (P = 0.010 REMICADE and azathioprine vs. azathioprine monotherapy; P = 0.324 REMICADE monotherapy vs. azathioprine monotherapy; P = 0.065 REMICADE and azathioprine vs. REMICADE monotherapy).

A final safety evaluation for those patients who entered the extension study occurred at week 54. The proportion of patients with 1 or more serious adverse events during the study was 27 percent (n=43) in the AZA monotherapy treatment group, 24 percent (n=39) in the REMICADE monotherapy treatment group, and 15 percent (n=27) in the combined REMICADE and AZA treatment group. No new serious adverse events, such as opportunistic infections, malignancies or death, were reported between weeks 30 and 54.

Dr. William J. Sandborn, Inflammatory Bowel Disease Clinic, Mayo Clinic, and principal investigator for the SONIC trial, will present the results of the SONIC extension trial on Tuesday, June 2 at 3:30 PM at the annual Digestive Disease Week meeting.

In 1998, REMICADE became the first anti-T
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... in the U.S. and XIAPEX ® in the ... will present a corporate overview at the 21 st ... The presentation will take place on Friday, September 26, ... in New York, NY . A live ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... General Dynamics Information Technology, a business unit of General ... a contract to support the U.S. Army Medical Department,s ... facilities and transition to newly constructed facilities. The indefinite ... by the U.S. Army Corps of Engineers, has a ...
... Oct. 12 Misonix, Inc. (Nasdaq: MSON ... medical device technology, which worldwide is used for acute ... its non-exclusive distribution arrangement in the United States with ... As a result, Misonix will assume exclusive ...
Cached Medicine Technology:General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities 2General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities 3Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S. 2
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
(Date:9/19/2014)... Albany,NY (PRWEB) September 19, 2014 ... Dr. Reed Ference, is excited to announce the ... with periodontal disease, gingivitis and those needing dental ... the LANAP® laser treatment removes the fear factor ... no stitches, less discomfort and bleeding make, this ...
(Date:9/19/2014)... 2014 York University researchers say a simple ... to detect heightened risk for developing Alzheimer,s disease ... telltale behavioural signs of dementia., Faculty of Health ... who led the study asked the participants to ... on dual screen laptop computers. The test aimed ...
(Date:9/19/2014)... 2014 Recent financial data reveled ... increased their sales by 7% in the last quarter ... industry can be used as a bellwether to determine ... This data has been proven to show trends with ... transportation. Other non-trucking data is largely influenced by international ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... , Recent CBO analysis ... 3 A new actuarial analysis by Oliver Wyman, Inc. ... market will be 54 percent higher than they are today ... Protection and Affordable Care Act (PPACA), excluding the impact of ...
... a new factor that is necessary for the development ... of malignant childhood brain cancer. HHMI investigator Huda Y. ... medulloblastoma from developing in mice by shutting down production ... team,s findings, reported in the December 4, 2009, issue ...
... , NEW YORK, Dec. ... H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic ... at least 6,500 fatalities. Since there is no longer ... undoubtedly understate the real situation. , (Photo: ...
... , CHICAGO, Dec. 3 An ... called platelet-rich plasma therapy (PRP), is showing strong potential ... a prominent dental researcher and editor of the ... Rutkowski, DMD, PhD, reported at the recent annual scientific ...
... low number of new cases created by a single ... as vaccination, social distancing and the use of antiviral ... the virus, suggests an epidemiological modelling study http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091807 ... Medical Association Journal ) www.cmaj.ca . ...
... ... specializing in the emerging medical travel space, announced that international medical quality authority, Dr. ... ... 2009 –- Satori World Medical, a leading global healthcare company specializing in the emerging ...
Cached Medicine News:Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4Health News:Researchers identify gene that spurs deadly brain cancer 2Health News:Researchers identify gene that spurs deadly brain cancer 3Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: